Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) and CG Oncology (NASDAQ:CGON)

BioCryst Pharmaceuticals (NASDAQ:BCRX) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares BioCryst Pharmaceuticals and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-38.18%	N/A	-28.14%
CG Oncology	N/A	N/A	N/A

Insider and Institutional Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BioCryst Pharmaceuticals and CG Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0	1	5	0	2.83
CG Oncology	0	0	8	1	3.11

BioCryst Pharmaceuticals currently has a consensus price target of $14.17, suggesting a potential upside of 73.19%. CG Oncology has a consensus price target of $63.88, suggesting a potential upside of 75.24%. Given CG Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than BioCryst Pharmaceuticals.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and CG Oncology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$382.24 million	4.42	-$226.54 million	($1.07)	-7.64
CG Oncology	$650,000.00	3,736.97	-$48.61 million	N/A	N/A

CG Oncology has lower revenue, but higher earnings than BioCryst Pharmaceuticals.

Summary

CG Oncology beats BioCryst Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.